

Ludger Klimek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3571023/publications.pdf>

Version: 2024-02-01

231
papers

14,134
citations

18482

62
h-index

30087

103
g-index

346
all docs

346
docs citations

346
times ranked

9132
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 vaccinesâ€”The way forward. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 15-16.	5.7	3
2	The effect of allergy and asthma as a comorbidity on the susceptibility and outcomes of COVID-19. <i>International Immunology</i> , 2022, 34, 177-188.	4.0	27
3	Development and validation of combined symptomâ€”medication scores for allergic rhinitis*. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2147-2162.	5.7	32
4	Cannabisâ€”related allergies: An international overview and consensus recommendations. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2038-2052.	5.7	23
5	EAACI position paper on the clinical use of the bronchial allergen challenge: Unmet needs and research priorities. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1667-1684.	5.7	12
6	Allergic patients during the COVID-19 pandemicâ€”Clinical practical considerations: An European Academy of Allergy and Clinical Immunology survey. <i>Clinical and Translational Allergy</i> , 2022, 12, e12097.	3.2	13
7	Allergies and COVID-19 vaccines: An ENDA/EAACI Position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2292-2312.	5.7	55
8	COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicalsâ€”EAACI recommendations. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2313-2336.	5.7	12
9	Clinical Assessment of Chronic Rhinosinusitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1406-1416.	3.8	6
10	Allergen immunotherapy during the COVID-19 pandemicâ€”A survey of the German Society for Allergy and Clinical Immunology. <i>Clinical and Translational Allergy</i> , 2022, 12, e12134.	3.2	6
11	Allergen immunotherapy in MASKâ€”air users in real-life: Results of a Bayesian mixed-effects model. <i>Clinical and Translational Allergy</i> , 2022, 12, e12128.	3.2	9
12	Behavioural patterns in allergic rhinitis medication in Europe: A study using MASKâ€”air [®] real-world data. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2699-2711.	5.7	17
13	Rhinitis allergica in storage mite allergy. <i>Allergo Journal International</i> , 2022, 31, 59-68.	2.0	5
14	Automatic market research of mobile health apps for the self-management of allergic rhinitis. <i>Clinical and Experimental Allergy</i> , 2022, 52, 1195-1207.	2.9	9
15	Epithelial immune regulation of inflammatory airway diseases: Chronic rhinosinusitis with nasal polyps (CRSwNP). <i>Allergologie Select</i> , 2022, 6, 148-166.	3.1	4
16	Olfactory dysfunction is more severe in wild-type SARS-CoV-2 infection than in the Delta variant (B.1.617.2). <i>World Allergy Organization Journal</i> , 2022, 15, 100653.	3.5	12
17	Comparison of rhinitis treatments using MASKâ€”air [®] data and considering the minimal important difference. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3002-3014.	5.7	8
18	Olfactory and gustatory disorders in COVID-19. <i>Allergo Journal International</i> , 2022, 31, 243-250.	2.0	14

#	ARTICLE	IF	CITATIONS
19	Presentation of airway and general symptoms in COVID-19 caused by dominant <sc>SARS-CoV-2</sc> variants: A follow-up on <sc>ARIA</sc> consensus. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3440-3444.	5.7	3
20	Management of suspected and confirmed COVID-19 (<sc>SARS-CoV-2</sc>) vaccine hypersensitivity. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3426-3434.	5.7	11
21	Update about Oralair® as a treatment for grass pollen allergic rhinitis. Human Vaccines and Immunotherapeutics, 2022, 18, .	3.3	2
22	Prevalence of acute olfactory dysfunction differs between variants of SARS-CoV-2” results from chemosensitive testing in wild type, VOC alpha (B.1.1.7) and VOC delta (B.1617.2). European Archives of Oto-Rhino-Laryngology, 2022, 279, 5445-5447.	1.6	12
23	Placebo effects in allergen immunotherapy” An EAACI Task Force Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 629-647.	5.7	31
24	Telemedicine allows quantitative measuring of olfactory dysfunction in COVID-19. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 868-870.	5.7	23
25	COVID-19 pandemic: Practical considerations on the organization of an allergy clinic” An EAACI/ARIA Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 648-676.	5.7	79
26	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190.	5.7	46
27	ARIA” EAACI statement on asthma and COVID-19 (June 2, 2020). Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 689-697.	5.7	57
28	Management of patients with chronic rhinosinusitis during the COVID-19 pandemic” An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 677-688.	5.7	33
29	The Debate: Regular Versus As-Needed Use of Intranasal Corticosteroids for a Patient-Centered Approach. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1374-1375.	3.8	3
30	EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. Journal of Allergy and Clinical Immunology, 2021, 147, 29-36.	2.9	178
31	Efficacy of broccoli and glucoraphanin in COVID-19: From hypothesis to proof-of-concept with three experimental clinical cases. World Allergy Organization Journal, 2021, 14, 100498.	3.5	27
32	Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1041-1052.	5.7	38
33	Practical recommendations for the allergological risk assessment of the COVID-19 vaccination ” a harmonized statement of allergy centers in Germany. Allergologie Select, 2021, 5, 72-76.	3.1	22
34	COVID-19 vaccination and allergen immunotherapy (AIT) - A position paper of the German Society for Applied Allergology (AeDA) and the German Society for Allergology and Clinical Immunology (DGAKI). Allergologie Select, 2021, 5, 251-259.	3.1	9
35	COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologics) ” A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergo. Allergologie Select, 2021, 5, 140-147.	3.1	28
36	The Nose as a Route for Therapy: Part 1. Pharmacotherapy. Frontiers in Allergy, 2021, 2, 638136.	2.8	12

#	ARTICLE	IF	CITATIONS
37	Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA. <i>Allergo Journal International</i> , 2021, 30, 51-55.	2.0	55
38	CpG Adjuvant in Allergen-Specific Immunotherapy: Finding the Sweet Spot for the Induction of Immune Tolerance. <i>Frontiers in Immunology</i> , 2021, 12, 590054.	4.8	21
39	Telemedicine in allergology: practical aspects. <i>Allergo Journal International</i> , 2021, 30, 119-129.	2.0	13
40	Appropriateness for SARS-CoV-2 vaccination for otolaryngologist and head and neck surgeons in case of pregnancy, breastfeeding, or childbearing potential: Yo-IFOS and CEORL-HNS joint clinical consensus statement. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 4091-4099.	1.6	2
41	Practical handling of allergic reactions to COVID-19 vaccines. <i>Allergo Journal International</i> , 2021, 30, 79-95.	2.0	25
42	Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e362-e365.	2.4	24
43	Heterogeneity of the pharmacologic treatment of allergic rhinitis in Europe based on MIDAS and OTCims platforms. <i>Clinical and Experimental Allergy</i> , 2021, 51, 1033-1045.	2.9	8
44	Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA ² LEN consensus. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2354-2366.	5.7	31
45	The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1805-1812.	3.8	14
46	Technical standards in allergen exposure chambers worldwide – an EAACI Task Force Report. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3589-3612.	5.7	23
47	Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3307-3313.	5.7	92
48	ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines – An EAACI-ARIA Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1624-1628.	5.7	66
49	Effects of allergen immunotherapy in the MASK-air study: a proof-of-concept analysis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3212-3214.	5.7	14
50	Inhaled corticosteroids in early COVID-19 – A tale of many facets. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3540-3542.	5.7	3
51	COVID-19 pandemic and allergen immunotherapy – an EAACI survey. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3504-3516.	5.7	26
52	Allergen immunotherapy: The growing role of observational and randomized trial – “Real World Evidence”. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2663-2672.	5.7	39
53	Venom Immunotherapy: From Proteins to Product to Patient Protection. <i>Toxins</i> , 2021, 13, 616.	3.4	3
54	Management of anaphylaxis due to COVID-19 vaccines in the elderly. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2952-2964.	5.7	16

#	ARTICLE	IF	CITATIONS
55	Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASK ^{air} ®. <i>Clinical and Translational Allergy</i> , 2021, 11, e12062.	3.2	31
56	Dogmas, challenges, and promises in phase III allergen immunotherapy studies. <i>World Allergy Organization Journal</i> , 2021, 14, 100578.	3.5	3
57	Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1141-1153.	10.7	263
58	Guideline (S2k) on acute therapy and management of anaphylaxis: 2021 update. <i>Allergo Journal International</i> , 2021, 30, 1-25.	2.0	78
59	COVID-19: Recovery from Chemosensory Dysfunction. A Multicentre study on Smell and Taste. <i>Laryngoscope</i> , 2021, 131, 1095-1100.	2.0	94
60	Nonpharmacological measures to prevent allergic symptoms in pollen allergy: A critical review. <i>Allergologie Select</i> , 2021, 5, 349-360.	3.1	7
61	Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 70-80.e3.	2.9	272
62	Pollen season is reflected on symptom load for grass and birch pollen-induced allergic rhinitis in different geographic areas – An EAACI Task Force Report. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1099-1106.	5.7	34
63	Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. <i>Clinical and Translational Allergy</i> , 2020, 10, 1.	3.2	110
64	State-of-the-art in marketed adjuvants and formulations in Allergen Immunotherapy: A position paper of the European Academy of Allergy and Clinical Immunology (EAACI). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 746-760.	5.7	42
65	MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis. <i>Journal of Asthma and Allergy</i> , 2020, Volume 13, 633-645.	3.4	8
66	The Loss of Smell and Taste in the COVID-19 Outbreak: a Tale of Many Countries. <i>Current Allergy and Asthma Reports</i> , 2020, 20, 61.	5.3	127
67	Therapy of allergic rhinitis in routine care: evidence-based benefit assessment of freely combined use of various active ingredients. <i>Allergo Journal International</i> , 2020, 29, 129-138.	2.0	5
68	Effect of Specific Immunoglobulin E Response and Comorbidities on Effectiveness of MP-AzeFlu in a Real-Life Study. <i>International Archives of Allergy and Immunology</i> , 2020, 181, 754-764.	2.1	2
69	Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma. <i>Clinical and Molecular Allergy</i> , 2020, 18, 15.	1.8	11
70	Treatment of allergic rhinitis during and outside the pollen season using mobile technology. <i>A MASK study</i> . <i>Clinical and Translational Allergy</i> , 2020, 10, 62.	3.2	34
71	A compendium answering 150 questions on COVID-19 and SARS-CoV-2. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2503-2541.	5.7	95
72	Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2764-2774.	5.7	75

#	ARTICLE	IF	CITATIONS
73	Is diet partly responsible for differences in COVID-19 death rates between and within countries?. <i>Clinical and Translational Allergy</i> , 2020, 10, 16.	3.2	97
74	Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EEAACI statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2440-2444.	5.7	114
75	Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air [®] App. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1672-1688.	5.7	32
76	Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EEAACI statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1546-1554.	5.7	87
77	Clinical trials in allergen immunotherapy in the age group of children and adolescents: current concepts and future needs. <i>Clinical and Translational Allergy</i> , 2020, 10, 11.	3.2	9
78	German Respiratory Society guidelines for diagnosis and treatment of adults suffering from acute, subacute and chronic cough. <i>Respiratory Medicine</i> , 2020, 170, 105939.	2.9	14
79	In-vivo diagnostic test allergens in Europe: A call to action and proposal for recovery plan- An EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2161-2169.	5.7	23
80	A new form of irritant rhinitis to filtering facepiece particle (FFP) masks (FFP2/N95/KN95 respirators) during COVID-19 pandemic. <i>World Allergy Organization Journal</i> , 2020, 13, 100474.	3.5	27
81	European Position Paper on Rhinosinusitis and Nasal Polyps 2020. <i>Rhinology</i> , 2020, 58, 1-464.	1.3	1,555
82	Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA. <i>Allergologie Select</i> , 2020, 4, 44-52.	3.1	23
83	Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie - ein Positionspapier von AeDA, DGAKI, GPA, A-GAI, LGAI, A-GP, ARIA und EAACI. <i>Allergologie</i> , 2020, 43, 255-271.	0.1	9
84	ARIA masterclass 2018: From guidelines to real-life implementation. <i>Rhinology</i> , 2019, 57, 0-0.	1.3	6
85	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. <i>Allergo Journal International</i> , 2019, 28, 255-276.	2.0	22
86	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. <i>Clinical and Translational Allergy</i> , 2019, 9, 44.	3.2	87
87	Development of subcutaneous allergen immunotherapy (part 2): preventive aspects and innovations. <i>Allergo Journal International</i> , 2019, 28, 107-119.	2.0	13
88	Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 135-143.e6.	2.9	101
89	Evolution of subcutaneous allergen immunotherapy (part 1): from first developments to mechanism-driven therapy concepts. <i>Allergo Journal International</i> , 2019, 28, 78-95.	2.0	16
90	Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. <i>Clinical and Translational Allergy</i> , 2019, 9, 16.	3.2	81

#	ARTICLE	IF	CITATIONS
91	Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 970-977.	2.9	30
92	2019 ARIA Care pathways for allergen immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2087-2102.	5.7	140
93	Mobile Technology in Allergic Rhinitis: Evolution in Management or Revolution in Health and Care?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2511-2523.	3.8	44
94	Strong dose response after immunotherapy with PQ grass using conjunctival provocation testing. <i>World Allergy Organization Journal</i> , 2019, 12, 100075.	3.5	11
95	Perspectives in allergen immunotherapy: 2019 and beyond. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 3-25.	5.7	113
96	Diagnosis and management of <sc>NSAID</sc>â€œExacerbated Respiratory Disease (Nâ€œ<sc>ERD</sc>)â€œa <sc>EAACI</sc> position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 28-39.	5.7	247
97	<sc>ARIA</sc> pharmacy 2018 â€œAllergic rhinitis care pathways for community pharmacyâ€œ. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1219-1236.	5.7	52
98	Adherence to treatment in allergic rhinitis using mobile technology. The <sc>MASK</sc> Study. <i>Clinical and Experimental Allergy</i> , 2019, 49, 442-460.	2.9	73
99	Current therapeutical strategies for allergic rhinitis. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 83-89.	1.8	36
100	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 864-879.	2.9	103
101	Intralymphatic Immunotherapy: Update and Unmet Needs. <i>International Archives of Allergy and Immunology</i> , 2019, 178, 141-149.	2.1	71
102	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. <i>Allergologie Select</i> , 2019, 3, 22-50.	3.1	70
103	Allergische Rhinitis. , 2019, , 261-269.		0
104	Impact of increasing treatment rates on cost-effectiveness of subcutaneous immunotherapy (SCIT) in respiratory allergy: a decision analytic modelling approach. <i>European Journal of Health Economics</i> , 2018, 19, 1229-1242.	2.8	7
105	Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the <sc>MASK</sc> study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1622-1631.	5.7	69
106	Subtyping of polyposis nasi: phenotypes, endotypes and comorbidities. <i>Allergo Journal International</i> , 2018, 27, 56-65.	2.0	54
107	EAACI Position paper on the standardization of nasal allergen challenges. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1597-1608.	5.7	161
108	Allergen-specific immunotherapy with storage mites. <i>Allergo Journal International</i> , 2018, 27, 15-19.	2.0	8

#	ARTICLE	IF	CITATIONS
109	Treatment of allergic rhinitis using mobile technology with real-world data: The MASK observational pilot study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1763-1774.	5.7	94
110	Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 497-509.e9.	2.9	84
111	Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 77-92.	5.7	54
112	Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 529-538.e13.	2.9	255
113	Emerging roles of innate lymphoid cells in inflammatory diseases: Clinical implications. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 837-850.	5.7	79
114	National clinical practice guidelines for allergen immunotherapy: An international assessment applying AGREE-II. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 664-672.	5.7	35
115	Current practice of allergy diagnosis and the potential impact of regulation in Europe. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 323-327.	5.7	17
116	Perspectives in allergen immunotherapy: 2017 and beyond. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 5-23.	5.7	76
117	Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States: An analysis from the EAACI AIT Guidelines Project. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 816-826.	5.7	67
118	Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 64-76.	5.7	72
119	Adrenaline in the Acute Treatment of Anaphylaxis. <i>Deutsches Ärzteblatt International</i> , 2018, 115, 528-534.	0.9	35
120	What Do We Really Know About Intralymphatic Immunotherapy?. <i>Current Treatment Options in Allergy</i> , 2018, 5, 415-423.	2.2	3
121	Recent developments and highlights in allergen immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2274-2289.	5.7	55
122	MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. <i>Clinical and Translational Allergy</i> , 2018, 8, 45.	3.2	104
123	POLLAR: Impact of air POLLution on Asthma and Rhinitis; a European Institute of Innovation and Technology Health (EIT Health) project. <i>Clinical and Translational Allergy</i> , 2018, 8, 36.	3.2	70
124	SCIT with a high-dose house dust mite allergoid is well tolerated: safety data from pooled clinical trials and more than 10 years of daily practice analyzed in different subgroups. <i>Allergo Journal International</i> , 2018, 27, 131-139.	2.0	21
125	Reliability of a New Symptom Score in a Titrated Quantitative Conjunctival Provocation Test Supported by an Objective Photodocumentation. <i>International Archives of Allergy and Immunology</i> , 2018, 176, 215-224.	2.1	8
126	The Work Productivity and Activity Impairment Allergic Specific (WPAI-AS) Questionnaire Using Mobile Technology: The MASK Study. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2018, 28, 42-44.	1.3	37

#	ARTICLE	IF	CITATIONS
127	Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study. World Allergy Organization Journal, 2018, 11, 15.	3.5	33
128	Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases. Allergo Journal International, 2018, 27, 245-255.	2.0	38
129	AIT mit seltenen Allergenen: Eine (gesundheitspolitische) Bestandsaufnahme. Allergologie, 2018, 41, 416-426.	0.1	3
130	Sublingual Immunotherapy Dosing Regimens: What Is Ideal?. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1-10.	3.8	20
131	Google Trends terms reporting rhinitis and related topics differ in European countries. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1261-1266.	5.7	48
132	Pilot study of mobile phone technology in allergic rhinitis in European countries: the <sc>MASK</sc>-rhinitis study. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 857-865.	5.7	93
133	Visual analogue scales (VAS): Measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care. Allergo Journal International, 2017, 26, 16-24.	2.0	292
134	Clinical use of adjuvants in allergen-immunotherapy. Expert Review of Clinical Immunology, 2017, 13, 599-610.	3.0	46
135	Work productivity in rhinitis using cell phones: The <sc>MASK</sc> pilot study. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1475-1484.	5.7	69
136	Non-Allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1657-1665.	5.7	193
137	Defining pollen exposure times for clinical trials of allergen immunotherapy for pollen-induced rhinoconjunctivitis – an <sc>EAACI</sc> position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 713-722.	5.7	118
138	Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines – 2016 revision. Journal of Allergy and Clinical Immunology, 2017, 140, 950-958.	2.9	1,199
139	Allergic reactions to antibiotics – two sides of the same coin: clearly diagnose or reliably rule out. Allergo Journal International, 2017, 26, 212-218.	2.0	3
140	Allergen immunotherapy in allergic rhinitis: current use and future trends. Expert Review of Clinical Immunology, 2017, 13, 897-906.	3.0	27
141	Current Standards and Improvements in the Use of SLIT Tablets for Allergen Immunotherapy. Current Treatment Options in Allergy, 2017, 4, 286-289.	2.2	1
142	A possible role of stem cells in nasal polyposis. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1868-1873.	5.7	14
143	Neuronal Differentiation Capability of Nasal Polyps of Chronic Rhinosinusitis. Archivum Immunologiae Et Therapiae Experimentalis, 2017, 65, 431-443.	2.3	11
144	The benefit of molecular diagnostics in allergic rhinitis. Allergo Journal International, 2017, 26, 301-310.	2.0	4

#	ARTICLE	IF	CITATIONS
145	Dose-response relationship of a new Timothy grass pollen allergoid in comparison with a grass pollen allergoid. <i>Clinical and Experimental Allergy</i> , 2017, 47, 1445-1455.	2.9	16
146	Course of respiratory allergy by treatment strategy based on German routine data. <i>Allergo Journal International</i> , 2017, 26, 195-203.	2.0	7
147	European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real-life clinical assessment. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 462-472.	5.7	71
148	Epithelial-Mesenchymal Transition in Chronic Rhinosinusitis: Differences Revealed Between Epithelial Cells from Nasal Polyps and Inferior Turbinates. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2017, 65, 157-173.	2.3	38
149	Olfaction in patients with allergic rhinitis: an indicator of successful MP-AzeFlu therapy. <i>International Forum of Allergy and Rhinology</i> , 2017, 7, 287-292.	2.8	15
150	CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel Network) Good Practice in allergic rhinitis: a SUNFRIL report. <i>Clinical and Translational Allergy</i> , 2017, 7, 37.	3.2	36
151	Impact of changed legislation on skin tests: the present and future. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2016, 16, 465-468.	2.3	7
152	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 367-374.e2.	2.9	128
153	Limited availability of diagnostic allergens for patch testing compromises patient care. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 743-745.	0.8	3
154	Novel Allergen Immunotherapy Routes. <i>Current Treatment Options in Allergy</i> , 2016, 3, 102-112.	2.2	0
155	Evidence vs. efficacy in allergen-specific immunotherapy: Considerations using the example of tradable products in Germany. <i>Allergo Journal International</i> , 2016, 25, 38-43.	2.0	8
156	New opportunities for allergen immunotherapy using synthetic peptide immuno-regulatory epitopes (SPIRES). <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1123-1135.	3.0	20
157	Recent pharmacological developments in the treatment of perennial and persistent allergic rhinitis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 657-669.	1.8	14
158	SQ house dust mite (HDM) SLIT-tablet provides clinical improvement in HDM-induced allergic rhinitis. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 369-377.	3.0	19
159	A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT birch pollen extract for the treatment of allergic rhinitis: results of a phase II study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 99-107.	5.7	44
160	Effectiveness of allergic rhinitis treatments in real-life with a focus on MP-AzeFlu. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 705-714.	3.1	1
161	Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and) Tj ETQq1 1 0.784314 mgBT /Overlock 10 T	2.4	10
162	Adaptive Desaktivierung bei Analgetikaintoleranz. , 2016, , 607-612.		0

#	ARTICLE	IF	CITATIONS
163	MACVIA-ARIA Sentinel Network for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1372-1392.	5.7	160
164	The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey. <i>Clinical and Translational Allergy</i> , 2015, 5, 39.	3.2	82
165	Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1â€œV in a randomized controlled trial. <i>Clinical and Translational Allergy</i> , 2015, 5, 28.	3.2	48
166	Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: Results from a noninterventional study. <i>Allergy and Asthma Proceedings</i> , 2015, 36, 40-47.	2.2	49
167	Clinically relevant outcome measures for new pharmacotherapy, allergen avoidance and immunotherapy trials in allergic rhinoconjunctivitis. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2015, 15, 197-203.	2.3	7
168	Diagnostic test allergens used for <i>inÂvivo</i> diagnosis of allergic diseases are at risk: a European Perspective. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1329-1331.	5.7	43
169	Authorised allergen products for intracutaneous testing may no longer be available in Germany. <i>Allergo Journal International</i> , 2015, 24, 84-93.	2.0	22
170	Guidelines on the management of IgE-mediated food allergies. <i>Allergo Journal International</i> , 2015, 24, 256-293.	2.0	129
171	SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. <i>Annals of Allergy, Asthma and Immunology</i> , 2015, 114, 134-140.e1.	1.0	84
172	Is The Allergen Really Needed in Allergy Immunotherapy?. <i>Current Treatment Options in Allergy</i> , 2015, 2, 72-82.	2.2	36
173	Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of) Tj ETQq1 1 0.784314 rgBT /Over Expert Opinion on Pharmacotherapy, 2015, 16, 913-928.	1.8	28
174	Mites and other indoor allergens â€œ from exposure to sensitization and treatment. <i>Allergo Journal International</i> , 2015, 24, 68-80.	2.0	28
175	The influence of European legislation on the use of diagnostic test allergens for nasal allergen provocation in routine care of patients with allergic rhinitis. <i>Rhinology</i> , 2015, 53, 260-269.	1.3	11
176	S3-Guideline on allergy prevention: 2014 update. <i>Allergo Journal International</i> , 2014, 23, 186-199.	2.0	58
177	Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1059-1067.	3.0	26
178	Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases. <i>Allergo Journal International</i> , 2014, 23, 282-319.	2.0	338
179	Old, Wise and Allergic: Allergies Are No Longer Solely Diseases of the Grandchildren. <i>International Archives of Allergy and Immunology</i> , 2014, 163, 75-76.	2.1	5
180	Aspirin Desensitization: Useful Treatment for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Aspirin-Exacerbated Respiratory Disease (AERD)?. <i>Current Allergy and Asthma Reports</i> , 2014, 14, 441.	5.3	32

#	ARTICLE	IF	CITATIONS
181	A high polymerized grass pollen extract is efficacious and safe in a randomized double-blind, placebo-controlled study using a novel up-dosing cluster-protocol. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 1629-1638.	5.7	37
182	A prospective study comparing the efficacy and safety of two sublingual birch allergen preparations. <i>Clinical and Translational Allergy</i> , 2014, 4, 23.	3.2	11
183	Guideline for acute therapy and management of anaphylaxis. <i>Allergo Journal International</i> , 2014, 23, 96-112.	2.0	210
184	A critical appraisal of analyzing nasal provocation test results in allergen immunotherapy trials. <i>Rhinology</i> , 2014, 52, 137-141.	1.3	7
185	In-vitro-Diagnostik des ASS-Intoleranz- Syndroms (Aspirin-exacerbated Respiratory Disease: AERD). <i>Allergologie</i> , 2014, 37, 11-19.	0.1	7
186	Die adaptive Desaktivierungsbehandlung bei Patienten mit ASS-Intoleranz- Syndrom: Übersicht über ein ursächlich- orientiertes Therapieprinzip. <i>Allergologie</i> , 2014, 37, 26-33.	0.1	3
187	Immunotherapy of Allergic Rhinitis: New Therapeutic Opportunities with Virus-like Particles Filled with Cpg Motifs. <i>American Journal of Rhinology and Allergy</i> , 2013, 27, 206-212.	2.0	19
188	A comparison of immunotherapy delivery methods for allergen immunotherapy. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 465-475.	3.0	17
189	Allergic disorders of the respiratory tract – findings from a large patient sample in the German statutory health insurance system. <i>Allergo Journal</i> , 2013, 22, 366-373.	0.1	51
190	Specific Immunotherapy. <i>Deutsches A&#x0308;rztblatt International</i> , 2013, 110, 148-58.	0.9	33
191	Adjuvants for immunotherapy. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2012, 12, 648-657.	2.3	52
192	EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. <i>Clinical and Translational Allergy</i> , 2012, 2, 20.	3.2	97
193	A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy*. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 272-279.	5.7	59
194	Immunological effects and tolerability of a new fast up dosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 630-637.	5.7	18
195	Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study. <i>Clinical and Experimental Allergy</i> , 2012, 42, 936-945.	2.9	50
196	Allergen-Specific Immunotherapy: Which Outcome Measures are Useful in Monitoring Clinical Trials?. <i>Immunology and Allergy Clinics of North America</i> , 2011, 31, 289-309.	1.9	46
197	Assessment of clinical efficacy of CYT003̈QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. <i>Clinical and Experimental Allergy</i> , 2011, 41, 1305-1312.	2.9	125
198	Sublingual Allergen-Specific Immunotherapy Adjuvanted with Monophosphoryl Lipid A: A Phase I/IIa Study. <i>International Archives of Allergy and Immunology</i> , 2011, 154, 336-344.	2.1	93

#	ARTICLE	IF	CITATIONS
199	Therapeutic Index (TIX) for intranasal corticosteroids in the treatment of allergic rhinitis.. Rhinology, 2011, 49, 272-280.	1.3	15
200	Therapeutic Index (TIX) for intranasal corticosteroids in the treatment of allergic rhinitis. Rhinology, 2011, 49, 272-280.	1.3	26
201	Nasale Glukokortikosteroid- Therapie: Ein Update. Allergologie, 2011, 34, 307-318.	0.1	12
202	Cluster protocols in SCIT: enough evidence for practical use?. Current Opinion in Allergy and Clinical Immunology, 2010, 10, 188-193.	2.3	16
203	Safety aspects of Cluster immunotherapy with semi-depot allergen extracts in seasonal allergic rhinoconjunctivitis. European Archives of Oto-Rhino-Laryngology, 2010, 267, 245-250.	1.6	14
204	Guidelines of the German Respiratory Society for Diagnosis and Treatment of Adults Suffering from Acute or Chronic Cough. Pneumologie, 2010, 64, 701-711.	0.1	65
205	Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Allergologie, 2010, 33, 3-33.	0.1	11
206	Klinische Parameter zur Beurteilung der Wirksamkeit einer spezifischen Immuntherapie bei polleninduzierter Rhinitis allergica. Bestimmung von "œwell days" als ergÄnzendes Konzept. Allergologie, 2010, 33, 35-42.	0.1	1
207	Rupatadin "œ" Pharmakologie, klinische Wirksamkeit und therapeutische Sicherheit eines neuen Antihistamins mit zusÄtzlicher, PAF-antagonisierender Wirkung. Allergologie, 2010, 33, 429-440.	0.1	8
208	Safety of Two Cluster Schedules for Subcutaneous Immunotherapy in Allergic Rhinitis or Asthma Patients Sensitized to Inhalant Allergens. International Archives of Allergy and Immunology, 2009, 150, 102-108.	2.1	22
209	Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. Journal of Allergy and Clinical Immunology, 2009, 123, 167-173.e7.	2.9	303
210	Aspirin Intolerance: Does Desensitization Alter the Course of the Disease?. Immunology and Allergy Clinics of North America, 2009, 29, 669-675.	1.9	51
211	Clinical outcome measures of specific immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2009, 9, 208-213.	2.3	18
212	Allergologie. , 2009, , 287-309.		0
213	Spezifische Immuntherapie (SCIT) mit rekombinanten Allergenen: eine neue Therapieoption bei allergischer Rhinitis. Allergologie, 2008, 31, 503-513.	0.1	2
214	Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis. Respiratory Medicine, 2006, 100, 1706-1715.	2.9	43
215	Aspirin desensitization in aspirin intolerance: update on current standards and recent improvements. Current Opinion in Allergy and Clinical Immunology, 2006, 6, 161-166.	2.3	66
216	Intranasal trigeminal sensitivity in subjects with allergic rhinitis. European Archives of Oto-Rhino-Laryngology, 2006, 263, 86-90.	1.6	23

#	ARTICLE	IF	CITATIONS
217	Adaptive Desaktivierung bei ASS-intoleranten Patienten mit Polyposis nasi et sinuum – Möglichkeiten eines neuen Therapieprinzips mit intravenöser Applikation. <i>Allergologie</i> , 2006, 29, 322-331.	0.1	15
218	Eicosanoids, aspirin-intolerance and the upper airways--current standards and recent improvements of the desensitization therapy. <i>Journal of Physiology and Pharmacology</i> , 2006, 57 Suppl 12, 5-13.	1.1	11
219	The Effects of Short-Term Immunotherapy Using Molecular Standardized Grass and Rye Allergens Compared with Symptomatic Drug Treatment on Rhinoconjunctivitis Symptoms, Skin Sensitivity, and Specific Nasal Reactivity. <i>Otolaryngology - Head and Neck Surgery</i> , 2005, 133, 538-543.	1.9	23
220	Leitlinie der DGAI zur allergischen Rhinokonjunktivitis. <i>Allergologie</i> , 2003, 26, 147-162.	0.1	19
221	Cluster-Immuntherapie bei allergischer Rhino-Konjunktivitis. <i>Allergologie</i> , 2002, 25, 549-556.	0.1	6
222	The effect of short-term immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions. <i>Journal of Allergy and Clinical Immunology</i> , 1999, 103, 47-53.	2.9	44
223	Comparison of olfactory function in patients with seasonal and perennial allergic rhinitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1998, 53, 297-301.	5.7	63
224	Heterogeneity in the Polyclonal T Cell Response to Birch Pollen Allergens. <i>International Archives of Allergy and Immunology</i> , 1997, 114, 272-277.	2.1	14
225	Eosinophil Cationic Protein in Nasal Secretions and Blood Serum in Grass-Pollen Allergic Rhinitis. <i>American Journal of Rhinology & Allergy</i> , 1996, 10, 319-322.	2.2	8
226	Penicillinallergie (2): Limitierte Diagnostik und ihre Folgen. <i>Deutsches Ärzteblatt International</i> , 0, , .	0.9	0
227	Therapie der allergischen Rhinitis: Polymedikation – Fragen nach der Evidenz. , 0, , .		0
228	Chronische Rhinosinusitis mit Nasenpolypen: Biologika auf dem Prüfstand. , 0, , .		1
229	Allergische Rhinitis: Der Trend geht zu topischen Therapeutika. , 0, , .		0
230	ASS-Intoleranz-Syndrom: Aktuelle Optionen der Therapie. , 0, , .		2
231	Präzisionsmedizin in der Allergologie: Realistische Erwartungen kommunizieren. , 0, , .		0